Physician profile

John Michael Mccabe

Cardiovascular Disease · Winston Salem, NC

NPI 1598723660

$3,866.53

in general payments reported to CMS, 2019-2025

19 companies · $358 in 2025

The $358 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$913.06

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Novartis Pharmaceuticals Corporation $893.08 2019-2025
Astrazeneca Pharmaceuticals Lp $543.79 2019-2022
Abiomed $444.81 2019-2022
E.R. Squibb & Sons, L.L.C. $357.35 2019-2025 Eliquis, Camzyos
Amgen INC. $301.68 2019-2025 Repatha
Janssen Pharmaceuticals, INC $284.28 2019-2022
Zoll Services LLC (A/K/A Zoll Lifecor Corp) $227.06 2019-2024 Lifevest
Boston Scientific Corporation $170.81 2020-2025 Avvigo Guidance System
Boehringer Ingelheim Pharmaceuticals, INC. $132.59 2019-2025 Jardiance
Vital Connect, INC $128.60 2023-2025 Vitalpatch Rtm
Pfizer INC. $80.17 2019-2025
Cardiva Medical, INC. $72.07 2021
Medtronic, INC. $62.35 2024-2025 Linq II, Onyx Frontier
Inari Medical, INC. $50.67 2022-2024 Flowtriever Catheter, S, Ct Thrombectomy System Kit
Novo Nordisk INC $36.27 2025 Wegovy
Show all 19 companies
CompanyGeneral paymentsYearsTop products
Cvrx, INC. $25.58 2022
Medtronic Vascular, INC. $24.41 2019-2020
Edwards Lifesciences Corporation $15.95 2021
Bayer Healthcare Pharmaceuticals INC. $15.01 2025

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

John Michael Mccabe

$3,866.53

in general payments reported 2019-2025

Years
2019-2025
Top company
Novartis Pharmaceuticals Corporation
Context
The $358 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).

https://glasscript.com/doctor/344110/john-michael-mccabe

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.